FOSUN PHARMA (02196) has announced that its controlling subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd., has obtained drug registration approval from the National Medical Products Administration for its Dobutamine Hydrochloride Injection.
The newly approved indication is for the short-term supportive treatment of heart failure caused by decreased myocardial contractility in organic heart disease, including low cardiac output syndrome following open-heart surgery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments